The VLA2001 booster vaccination will be given at least seven months after completion of the primary vaccination series. The trial is currently ongoing in the UK and is supported by the National Institute for Health Research (NIHR). It is expected to provide topline data during the second quarter of 2022.
https://valneva.com/press-release/valnev...candidate/
https://valneva.com/press-release/valnev...candidate/